DoE development of ionic gradient liposomes: A successful approach to improve encapsulation, prolong anesthesia and...

Area of Science:

• Nanotechnology
• Pharmacology
• Drug Delivery Systems

Background:

• Etidocaine (EDC), a long-acting aminoamide anesthetic, was discontinued due to toxicity concerns.
• Ionic gradient liposomes (IGL) are advanced nanocarriers designed to enhance drug loading via ion gradients.

Purpose of the Study:

• To develop and characterize an optimized ionic gradient liposome formulation for etidocaine (IGL_EDC).
• To evaluate the in vitro and in vivo performance of IGL_EDC, focusing on safety and efficacy.
• To assess the potential for reintroducing etidocaine for pain management.

Main Methods:

• Formulation optimization using Design of Experiments.
• Characterization of IGL_EDC using Dynamic Light Scattering (DLS), Nanoparticle Tracking Analysis (NTA), Transmission Electron Microscopy (TEM/Cryo-TEM), Differential Scanning Calorimetry (DSC), and ¹H Nuclear Magnetic Resonance (NMR).
• In vitro release kinetics and cytotoxicity assays on Schwann cells.
• In vivo toxicity and anesthetic effect studies in Caenorhabditis elegans and rats.

Main Results:

• Optimized IGL_EDC achieved 41% encapsulation efficiency and demonstrated 180-day shelf stability.
• DSC and ¹H NMR confirmed EDC interaction with the lipid bilayer, indicating membrane permeation.
• In vitro, IGL_EDC provided sustained release over 24 hours and reduced EDC toxicity to Schwann cells by 50%.
• In vivo, IGL_EDC decreased EDC toxicity in Caenorhabditis elegans by 25% and extended anesthetic duration by one hour in rats.

Conclusions:

• The developed IGL_EDC formulation demonstrates improved safety and sustained efficacy compared to etidocaine alone.
• This novel liposomal drug delivery system shows promise for the potential reintroduction of etidocaine in clinical settings.
• IGL_EDC offers a viable strategy for managing operative and postoperative pain.